Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Acq. announced
CC transcript
Asset disposition
Appointed director

CTI BIOPHARMA CORP (CTI) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/28/2023 4 BVF PARTNERS L P/IL (10% Owner) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Unknown transaction of 3,989,130 shares @ $9.1, valued at $36.3M
Unknown transaction of 2,595,239 shares @ $9.1, valued at $23.6M
Unknown transaction of 702,505 shares @ $9.1, valued at $6.4M
Unknown transaction of 1,526,147 shares @ $9.1, valued at $13.9M
Unknown transaction of 43,139 shares @ $9.1, valued at $392.6k
Unknown transaction of 1,594 options to buy @ $0
Unknown transaction of 1,250 options to buy @ $0
Unknown transaction of 191 options to buy @ $0
Unknown transaction of 12 options to buy @ $0
Unknown transaction of 344 options to buy @ $0
Unknown transaction of 239 options to buy @ $0
03/16/2023 4 Craig Adam R (President and CEO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 900,000 options to buy @ $4.55, valued at $4.1M
03/16/2023 4 KIRSKE DAVID (EVP, CFO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 200,000 options to buy @ $4.55, valued at $910k
03/16/2023 4 Fong James K (EVP & Chief Commercial Officer) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 200,000 options to buy @ $4.55, valued at $910k
01/26/2023 4 Craig Adam R (President and CEO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Sold 83,200 shares @ $6, valued at $499.2k
Sold 2,117 shares @ $6.01, valued at $12.7k
Exercised 83,200 options to buy @ $0.8411, valued at $70k
Exercised 2,117 options to buy @ $0.8411, valued at $1.8k
01/26/2023 4 Fong James K (EVP & Chief Commercial Officer) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Sold 100,000 shares @ $6, valued at $600k
Granted 288,000 options to buy @ $0.9489, valued at $273.3k
Exercised 100,000 options to buy @ $0.9489, valued at $94.9k
01/03/2023 4 Craig Adam R (President and CEO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Sold 13,800 shares @ $6, valued at $82.8k
Granted 1,579 shares @ $5.1085, valued at $8.1k
Sold 12,000 shares @ $6, valued at $72k
Sold 700 shares @ $6.005, valued at $4.2k
Sold 4,400 shares @ $6.01, valued at $26.4k
Sold 84,683 shares @ $6.0133, valued at $509.2k
Exercised 13,800 options to buy @ $0.8411, valued at $11.6k
Exercised 12,000 options to buy @ $0.8411, valued at $10.1k
Exercised 700 options to buy @ $0.8411, valued at $588.8
Exercised 4,400 options to buy @ $0.8411, valued at $3.7k
Exercised 84,683 options to buy @ $0.8411, valued at $71.2k
01/03/2023 4 KIRSKE DAVID (EVP, CFO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Sold 13,174 shares @ $6, valued at $79k
Granted 214 shares @ $5.1085, valued at $1.1k
Sold 12,000 shares @ $6, valued at $72k
Sold 800 shares @ $6.005, valued at $4.8k
Sold 1,047 shares @ $6.01, valued at $6.3k
Sold 27,021 shares @ $6.011, valued at $162.4k
Exercised 13,174 options to buy @ $0.9489, valued at $12.5k
Exercised 12,000 options to buy @ $0.9489, valued at $11.4k
Exercised 800 options to buy @ $0.9489, valued at $759.1
Exercised 1,047 options to buy @ $0.9489, valued at $993.5
Exercised 27,021 options to buy @ $0.9489, valued at $25.6k
11/14/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/10/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/06/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/03/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/20/2022 4 KIRSKE DAVID (EVP, CFO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 9,516 shares @ $2.1165, valued at $20.1k
Sold 22,592 shares @ $6.02, valued at $136k
Exercised 22,592 options to buy @ $0.9489, valued at $21.4k
09/14/2022 4 Craig Adam R (President and CEO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Sold 242,300 shares @ $6.43, valued at $1.6M
Exercised 242,300 options to buy @ $0.8411, valued at $203.8k
08/16/2022 4 Craig Adam R (President and CEO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Bought 5,000 shares @ $5.5, valued at $27.5k
08/11/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/11/2022 4 Metzger Michael A (Director) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Sold 9,000 shares @ $6.5, valued at $58.5k
Sold 5,900 shares @ $6.51, valued at $38.4k
Sold 3,321 shares @ $6.52, valued at $21.7k
Sold 400 shares @ $6.53, valued at $2.6k
Sold 400 shares @ $6.54, valued at $2.6k
Sold 1,100 shares @ $6.55, valued at $7.2k
07/07/2022 4 Metzger Michael A (Director) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Sold 8,700 shares @ $5.9766, valued at $52k
Sold 51,963 shares @ $6.0512, valued at $314.4k
Sold 27,506 shares @ $6.1403, valued at $168.9k
Sold 3,331 shares @ $6.2255, valued at $20.7k
Exercised 91,500 options to buy @ $0.8411, valued at $77k
07/06/2022 4 Craig Adam R (President and CEO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 6,183 shares @ $2.1165, valued at $13.1k
Sold 27,000 shares @ $6, valued at $162k
Sold 27,000 shares @ $6, valued at $162k
Sold 18,223 shares @ $6.11, valued at $111.3k
Exercised 27,000 options to buy @ $0.8411, valued at $22.7k
Exercised 27,000 options to buy @ $0.8411, valued at $22.7k
Exercised 18,223 options to buy @ $0.8411, valued at $15.3k
06/17/2022 4 KIRSKE DAVID (EVP, CFO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Sold 10,000 shares @ $6, valued at $60k
Sold 50,000 shares @ $6.2501, valued at $312.5k
Exercised 10,000 options to buy @ $1, valued at $10k
Exercised 50,000 options to buy @ $3.3, valued at $165k
06/16/2022 4 KIRSKE DAVID (EVP, CFO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Sold 10,000 shares @ $5.5, valued at $55k
Exercised 10,000 options to buy @ $0.9489, valued at $9.5k
06/03/2022 4 Craig Adam R (President and CEO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Sold 27,000 shares @ $6, valued at $162k
Sold 27,000 shares @ $6, valued at $162k
Sold 18,223 shares @ $6.01, valued at $109.5k
Exercised 27,000 options to buy @ $0.8411, valued at $22.7k
Exercised 27,000 options to buy @ $0.8411, valued at $22.7k
Exercised 18,223 options to buy @ $0.8411, valued at $15.3k
03/11/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/11/2022 4 Tuckson Reed Vaughn (Director) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 80,000 options to buy @ $4.49, valued at $359.2k
03/11/2022 4 PERRY MATTHEW D (Director) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 80,000 options to buy @ $4.49, valued at $359.2k
03/11/2022 4 Parks Diane L. (Director) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 80,000 options to buy @ $4.49, valued at $359.2k
03/11/2022 4 Parkinson David Ross (Director) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 80,000 options to buy @ $4.49, valued at $359.2k
03/11/2022 4 Metzger Michael A (Director) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 80,000 options to buy @ $4.49, valued at $359.2k
03/11/2022 4 Fischer Laurent (Director) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 80,000 options to buy @ $4.49, valued at $359.2k
03/11/2022 4 KIRSKE DAVID (EVP, CFO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 1,782 shares @ $2.125, valued at $3.8k
Granted 1,817 shares @ $2.108, valued at $3.8k
Granted 280,000 options to buy @ $4.49, valued at $1.3M
03/11/2022 4 SEELEY BRUCE J. (EVP, COO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 3,164 shares @ $2.125, valued at $6.7k
Granted 3,241 shares @ $2.108, valued at $6.8k
Granted 280,000 options to buy @ $4.49, valued at $1.3M
03/11/2022 4 Craig Adam R (President and CEO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 3,178 shares @ $2.108, valued at $6.7k
Granted 1,115,000 options to buy @ $4.49, valued at $5M
12/02/2021 4 Craig Adam R (President and CEO) has filed a Form 4 on CTI BIOPHARMA CORP
Txns: Granted 5,000 shares @ $2.125, valued at $10.6k
Bought 1,322 shares @ $1.5249, valued at $2k
Bought 2,178 shares @ $1.525, valued at $3.3k
04/05/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy